# Drew M. Pardoll

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/drew-m-pardoll/

## Facts

| Field | Value |
| --- | --- |
| Citations | 169,138 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 166 |
| i10-index | 431 |
| Last Known Institution | Bloomberg (United States) |
| OpenAlex ID | https://openalex.org/A5066707073 |
| ORCID iD | https://orcid.org/0000-0001-6215-1013 |
| Works | 895 |

## Researcher papers

Showing 12 of 23.

- [Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer](https://scholariq.org/papers/safety-activity-and-immune-correlates-of-anti-pd-1-antibody-in-cancer/)
- [PD-1 Blockade in Tumors with Mismatch-Repair Deficiency](https://scholariq.org/papers/pd-1-blockade-in-tumors-with-mismatch-repair-deficiency/)
- [Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer](https://scholariq.org/papers/safety-and-activity-of-anti-pd-l1-antibody-in-patients-with-advanced-cancer/)
- [Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade](https://scholariq.org/papers/mismatch-repair-deficiency-predicts-response-of-solid-tumors-to-pd-1-blockade/)
- [Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates](https://scholariq.org/papers/phase-i-study-of-single-agent-anti-programmed-death-1-mdx-1106-in-refractory/)
- [Neoadjuvant PD-1 Blockade in Resectable Lung Cancer](https://scholariq.org/papers/neoadjuvant-pd-1-blockade-in-resectable-lung-cancer/)
- [Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape](https://scholariq.org/papers/immune-inhibitory-molecules-lag-3-and-pd-1-synergistically-regulate-t-cell/)
- [The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints](https://scholariq.org/papers/the-vigorous-immune-microenvironment-of-microsatellite-instable-colon-cancer-is/)
- [Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis](https://scholariq.org/papers/constitutive-stat3-activity-up-regulates-vegf-expression-and-tumor-angiogenesis/)
- [Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/overall-survival-and-long-term-safety-of-nivolumab-anti-programmed-death-1/)
- [Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer](https://scholariq.org/papers/evolution-of-neoantigen-landscape-during-immune-checkpoint-blockade-in-non-small/)
- [Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas](https://scholariq.org/papers/anti-pd-1-blockade-and-stereotactic-radiation-produce-long-term-survival-in-mice/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Immune Cell Function and Interaction](https://scholariq.org/topics/immune-cell-function-and-interaction/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [T-cell and B-cell Immunology](https://scholariq.org/topics/t-cell-and-b-cell-immunology/)

## Researcher university

- [Bloomberg (United States)](https://scholariq.org/institutions/bloomberg-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.